Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS

Key Points

• Coya Therapeutics reported a quarterly loss of $0.28 per share, beating analyst expectations by $0.08, though the company posted a negative net margin of 266.10% and negative return on equity of 55.86%.
• Shares rose 0.6% to $4.67 during Tuesday trading. The stock has traded between $3.71 and $7.75 over the past year, with a market capitalization of approximately $109.6 million.
• Analyst sentiment remains broadly positive, with six Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $15.33; institutional investors own 39.75% of the company.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.08, Zacks reports. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%.

Coya Therapeutics Trading Up 0.6%

Shares of NASDAQ COYA traded up $0.03 during mid-day trading on Tuesday, hitting $4.67. The company had a trading volume of 50,538 shares, compared to its average volume of 193,531. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The company has a market capitalization of $109.56 million, a price-to-earnings ratio of -4.11 and a beta of 0.61. The stock's 50-day moving average price is $4.86 and its 200-day moving average price is $4.67.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on COYA shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Friday, June 12th. Roth Capital initiated coverage on shares of Coya Therapeutics in a report on Friday, June 5th. They set a "buy" rating and a $12.00 price objective for the company. Finally, Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $15.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of COYA. Alyeska Investment Group L.P. bought a new position in shares of Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $4,205,000. Private Management Group Inc. purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $1,626,000. Marshall Wace LLP increased its position in shares of Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company's stock valued at $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Coya Therapeutics by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 197,988 shares of the company's stock valued at $1,149,000 after buying an additional 41,143 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source